Clinical Trials Logo

Clinical Trial Summary

This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer(NSCLC)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05118334
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact Xiuzhi Yu
Phone 0512-69566088
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date November 12, 2021
Completion date June 30, 2023